These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 21978982

  • 101. Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.
    Yamamoto Y, Takahashi Y, Imai K, Mishima N, Kagawa Y, Inoue Y.
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1517-24. PubMed ID: 26391520
    [Abstract] [Full Text] [Related]

  • 102. Clinical alertness to valproic acid-induced hyperammonemia--two case reports.
    Shan JC, Hsieh MH, Liu CC, Wen CC, Liu CM.
    J Psychopharmacol; 2010 Jun; 24(6):943-5. PubMed ID: 19304858
    [No Abstract] [Full Text] [Related]

  • 103. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.
    Garcia M, Huppertz HJ, Ziyeh S, Buechert M, Schumacher M, Mader I.
    Epilepsia; 2009 Mar; 50(3):486-92. PubMed ID: 19183221
    [Abstract] [Full Text] [Related]

  • 104.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 105.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 106. Noncirrhotic hyperammonaemic encephalopathy.
    Laish I, Ben Ari Z.
    Liver Int; 2011 Oct; 31(9):1259-70. PubMed ID: 21745294
    [Abstract] [Full Text] [Related]

  • 107.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 108. Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy.
    Viloria Alebesque A, Montes Castro N, Arcos Sánchez C, Vicente Gordo D.
    Neurologia (Engl Ed); 2020 Oct; 35(8):603-606. PubMed ID: 31331678
    [No Abstract] [Full Text] [Related]

  • 109. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M, Nakamura T, Okizuka Y, Oyazato Y, Kawasaki Y, Tsuneishi S, Sakaeda T, Matsuo M, Okumura K, Okamura N.
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [Abstract] [Full Text] [Related]

  • 110. Valproicacid-induced hyperammonemic encephalopathy in the emergency department.
    Pliego Cosano R, Moreno Rosauro JM, Clavero Olmos M.
    Emergencias; 2019 Oct; 31(5):364-365. PubMed ID: 31625314
    [No Abstract] [Full Text] [Related]

  • 111. Multifactorial non-cirrhotic hyperammonaemic encephalopathy.
    Triplett KE, Murray R, Anstey M.
    BMJ Case Rep; 2018 Mar 09; 2018():. PubMed ID: 29523611
    [Abstract] [Full Text] [Related]

  • 112. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
    Lind J, Nordlund P.
    Seizure; 2019 Jul 09; 69():20-24. PubMed ID: 30953957
    [Abstract] [Full Text] [Related]

  • 113. Fulminant progression of hyperammonaemic encephalopathy after treatment with valproate in a patient with ureterosigmoidostomy.
    Schwarz S, Georgiadis D, Schwab S, Gehlen F, Mayatepek E, Zoubaa S.
    J Neurol Neurosurg Psychiatry; 2002 Jul 09; 73(1):90-1. PubMed ID: 12082063
    [No Abstract] [Full Text] [Related]

  • 114. A reversible cause of coma in epilepsy.
    Kesav P, V Y V, Khurana D.
    BMJ Case Rep; 2012 Dec 13; 2012():. PubMed ID: 23239782
    [Abstract] [Full Text] [Related]

  • 115. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K.
    Seizure; 2015 Dec 13; 33():76-80. PubMed ID: 26599579
    [Abstract] [Full Text] [Related]

  • 116. Non-hyperammonaemia valproate-induced encephalopathy: A case report.
    Chen L, Xu Z, Huang H.
    J Clin Pharm Ther; 2022 Mar 13; 47(3):415-419. PubMed ID: 34462930
    [Abstract] [Full Text] [Related]

  • 117. [Reversible encephalopathy caused by valproic acid in an adolescent with idiopathic generalised epilepsy].
    Raspall-Chaure M, Lainez E, Toledo M, Salas-Puig J, Macaya-Ruiz A, Roig-Quilis M.
    Rev Neurol; 2012 Dec 01; 55(11):663-8. PubMed ID: 23172093
    [Abstract] [Full Text] [Related]

  • 118. [Valproate-induced hyperammonemic encephalopathy].
    Diaz-Rangel M, Grande-Martin A, Monsalve-Naharro JA, Domingo-Chiva E, Cuesta-Montero P, Lopez-Perez A.
    Rev Neurol; 2017 Dec 16; 65(12):574-575. PubMed ID: 29235622
    [Abstract] [Full Text] [Related]

  • 119. In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.
    Monostory K, Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Tapodi A, Garami M.
    Epilepsia; 2016 Aug 16; 57(8):1339-40. PubMed ID: 27485380
    [No Abstract] [Full Text] [Related]

  • 120. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
    Solomon GE.
    Neurology; 2000 Aug 22; 55(4):606. PubMed ID: 10953214
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.